Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05005728 · ClinicalTrials.gov registry record · Phase 2
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2 study, sponsored by Xencor.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT05005728: Completed Phase 2 study, sponsored by Xencor.
NCT05005728 is a Phase 2 study that has completed, run by Xencor. The registered enrollment target is 72 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05005728, a Phase 2 study, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior therapy.
Interventions
- COMBINATION_PRODUCT vudalimab + carboplatin + cabazitaxel
- COMBINATION_PRODUCT vudalimab + olaparib
- BIOLOGICAL vudalimab monotherapy
- COMBINATION_PRODUCT vudalimab + docetaxel
- COMBINATION_PRODUCT vudalimab + cabazitaxel or docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2021-10-22 |
| Est. Completion | 2025-06-10 |
| Phase | Phase 2 |
What the finished NCT05005728 record still lists
NCT05005728 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower).
The record links to 0 conditions, and to 5 interventions - of which vudalimab + carboplatin + cabazitaxel is the first listed.
NCT05005728 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05005728 about?
NCT05005728 is a clinical study titled "XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer". This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior therapy.
What is the current status of trial NCT05005728?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2021-10-22. Estimated completion is 2025-06-10.
What interventions are being tested in trial NCT05005728?
The interventions under investigation include: vudalimab + carboplatin + cabazitaxel (COMBINATION_PRODUCT), vudalimab + olaparib (COMBINATION_PRODUCT), vudalimab monotherapy (BIOLOGICAL), vudalimab + docetaxel (COMBINATION_PRODUCT), vudalimab + cabazitaxel or docetaxel (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05005728?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05005728's enrollment target sits among peer trials
72 925th of 2000 higher than 1,065 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI